Advertisement
Journal Home
Search for

Volume 18, Issue 9, Pages 629-634 (September 2007)


View previous. 9 of 10 View next.

HUM5007, a novel combination of thermogenic compounds, and 3-acetyl-7-oxo-dehydroepiandrosterone: each increases the resting metabolic rate of overweight adults

John L. ZenkaCorresponding Author Informationemail address, Joy L. Frestedta, Michael A. Kuskowskib

Received 25 September 2006; received in revised form 6 November 2006; accepted 10 November 2006. published online 06 April 2007.

Abstract 

This study tested the hypothesis that 3-acetyl-7-oxo-dehydroepiandrosterone alone (7-Keto) and in combination with calcium citrate, green tea extract, ascorbic acid, chromium nicotinate and cholecalciferol (HUM5007) will increase the resting metabolic rate (RMR) of overweight subjects maintained on a calorie-restricted diet. In this randomized, double-blind, placebo-controlled, crossover trial, overweight adults on a calorie-restricted diet were randomized to three 7-day treatment periods with 7-Keto, HUM5007 or placebo. Resting metabolic rate was measured by indirect calorimetry at the beginning and end of each treatment period with a 7-day washout between testing periods. Of 45 subjects enrolled, 40 completed the study (30 women, 10 men; mean age, 38.5 years; mean mass index, 32.0 kg/m2). During the placebo treatment, RMR decreased by 3.9% (75±111 kcal/day; mean±S.D.); however, RMR increased significantly by 1.4% (21±115 kcal/day) and 3.4% (59±118 kcal/day) during the 7-Keto and HUM5007 treatment periods, respectively (each compared to placebo, P=.001). No significant differences were found between the treatment periods with respect to compliance or adverse events. In this study, the administration of HUM5007 or 7-Keto reversed the decrease in RMR normally associated with dieting. HUM5007 and 7-Keto increased RMR above basal levels and may benefit obese individuals with impaired energy expenditure. HUM5007 and 7-Keto were generally well tolerated and no serious adverse events were reported.

a Department of Clinical Affairs, Minnesota Applied Research Center, Edina, MN 55435, USA

b Department of Psychiatry, Geriatric Research Education and Clinical Center, Veterans Administration Medical Center, Minneapolis, MN 55417, USA

Corresponding Author InformationCorresponding author. Tel.: +1 952 400 0402; fax: +1 952 937 7667.

 This trial was sponsored by Humanetics Corporation, Eden Prairie, MN, USA.

PII: S0955-2863(07)00012-5

doi:10.1016/j.jnutbio.2006.11.008


View previous. 9 of 10 View next.

Advertisement